# Erlotinib in Combination With Cetuximab

> **NCT00895362** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 65 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00895362
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895362, "Erlotinib in Combination With Cetuximab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00895362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*